

Cellestia awarded Innosuisse Grant to advance a groundbreaking Graft versus Host Disease prevention therapy

Basel, Switzerland – 11 January 2024 – Cellestia Biotech AG (Cellestia) is proud to announce its selection for a CHF 2 million grant from the Swiss Innovation Agency, Innosuisse, as part of their Start-up Innovation project to advance to clinical Proof of Concept a first-in-class therapy for prevention of Graft vs Host Disease (GvHD).

The project aims at developing CB-103 as first-in-class drug to prevent GvHD in allogeneic-Hematopoetic Stem Cell Transplant (HSCT) patients. With this novel approach, Cellestia envisions a transformative shift in the management of GvHD from treatment to prevention.

"We extend our sincere thanks to Innosuisse for recognizing the potential of CB-103 in enhancing the lives of patients grappling with GvHD" said Raj Lehal, CEO of Cellestia.

About GVHD

GvHD stands as the leading non-relapse-related cause of mortality in individuals undergoing allo-HSCT, impacting over 50% of the patients. The standard of care for prevention of GvHD is insufficient to prevent its occurrence, contributing to the persistent high mortality rates in this patient population.

About Innosuisse

Innosuisse is the Swiss Innovation Agency. Its mission is to promote science-based innovation in the interest of the economy and society in Switzerland. The core of Innosuisse funding is the support of innovation projects: innovative organizations such as companies and start-ups develop new services and products together with universities and research institutions.


About Cellestia Biotech

Cellestia Biotech AG (Cellestia) is a fully integrated R&D company specialised in innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. The clinical stage drug candidate, CB-103, has demonstrated excellent safety profile and biological activity in a phase I clinical trial. Along with the ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD) thanks to the the generous support provided by Innosuisse.

For more information please contact:

Rajwinder Lehal, CEO +41 78 684 2450 raj.lehal@cellestia.com Gaudenz von Capeller, CFO +41 79 798 64 43 gaudenz.voncapeller@cellestia.com

Innovation project supported by



Innosuisse – Swiss Innovation Agency